Curadel Surgical Innovations, Inc. (CSI), founded in Natick, Massachusetts, holds exclusive global licensing rights from Curadel, LLC to develop, manufacture, market, and commercialize the FLARE portfolio of contrast agents for image-guided surgery. Their core mission is to enhance surgical precision by providing visual improvements to various anatomical structures, thereby improving surgical outcomes. The FLARE technology utilizes advanced imaging techniques to assist surgeons in identifying critical areas during procedures. CSI focuses on the healthcare market, particularly in surgical innovations.

Notable affiliated individuals include key members of the management team and board of directors who bring extensive experience in medical technology and business development. CSI has achieved significant milestones, including securing exclusive licensing rights and advancing the FLARE technology towards broader clinical adoption. Their impact on the medical field is profound, as they provide surgeons with enhanced visualization tools that improve the accuracy and safety of surgical procedures.